ESMO 2018: Nivolumab Plus Low-Dose Ipilimumab Shows Promise Against Microsatellite Instability-High Metastatic Colorectal Cancer
Immunotherapy benefits both treatment-naive and chemotherapy-resistant patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.